These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 8865530

  • 1. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K.
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [Abstract] [Full Text] [Related]

  • 2. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D.
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [Abstract] [Full Text] [Related]

  • 3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffmann A, Schmidt A, Beck H.
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [Abstract] [Full Text] [Related]

  • 4. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
    Luomanmäki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sörskog L, Vilkko P.
    J Intern Med; 1996 Aug; 240(2):85-92. PubMed ID: 8810934
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Büller HR.
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [Abstract] [Full Text] [Related]

  • 9. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis.
    Holmström M, Lindmarker P, Granqvist S, Johnsson H, Lockner D.
    Thromb Haemost; 1997 Aug; 78(2):803-7. PubMed ID: 9268175
    [Abstract] [Full Text] [Related]

  • 10. Dalteparin versus unfractionated heparin in critically ill patients.
    PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE.
    N Engl J Med; 2011 Apr 07; 364(14):1305-14. PubMed ID: 21417952
    [Abstract] [Full Text] [Related]

  • 11. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Gräve M, Patek F, Drexler M, Siemens HJ, Harenberg J, Weidinger G, Brom J, Haas S, TH-4 Study Group.
    Thromb Haemost; 2003 Aug 07; 90(2):252-9. PubMed ID: 12888872
    [Abstract] [Full Text] [Related]

  • 12. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF, Neuhart E.
    Thromb Haemost; 1996 Oct 07; 76(4):529-34. PubMed ID: 8902991
    [Abstract] [Full Text] [Related]

  • 13. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, Mateo AM, Carrera S, Gutiérrez V, Vaquero C.
    J Vasc Surg; 1999 Aug 07; 30(2):283-92. PubMed ID: 10436448
    [Abstract] [Full Text] [Related]

  • 14. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL, Perkins RB, Littell RD, Krasner CN, Duska LR.
    Obstet Gynecol; 2005 May 07; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [Abstract] [Full Text] [Related]

  • 15. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E, Araújo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto F, CLETRAT Investigators.
    Thromb Res; 2004 May 07; 114(3):149-53. PubMed ID: 15342210
    [Abstract] [Full Text] [Related]

  • 16. [Out-patient treatment of deep vein thrombosis: management and experience of two vascular care centres in Germany].
    Offermann M, Koepchen J, Graulich B.
    Dtsch Med Wochenschr; 2001 Oct 19; 126(42):1164-7. PubMed ID: 11607855
    [Abstract] [Full Text] [Related]

  • 17. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB, Cantor SB, Shih YC, Escalante CP, Rivera E, Elting LS.
    Support Care Cancer; 2004 Jul 19; 12(7):531-6. PubMed ID: 14986076
    [Abstract] [Full Text] [Related]

  • 18. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
    Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B, Sors H.
    Thromb Haemost; 1995 Dec 19; 74(6):1432-5. PubMed ID: 8772215
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
    Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E.
    Thromb Haemost; 1992 Jul 06; 68(1):14-8. PubMed ID: 1325076
    [Abstract] [Full Text] [Related]

  • 20. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J, Riess H, Büller HR, Brom J, Weidinger G, Huisman MV.
    Haematologica; 2003 Oct 06; 88(10):1157-62. PubMed ID: 14555312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.